CONTACT

PRODUCTS

The Hera Biotech Products

Built to Replace the Standard—Not to Just Improve It

One Engine. Two Tools. Built to Diagnose Differently

MetriDx™ and HERAfem™ aren’t two standalone products.

Two tools. One platform. Optimized for frontline care.

Each tool:

  • Collects biological and physical information from the tissue
  • Analyzes biological complexity using adaptive AI/ML models.
  • Outputs are elaborated to improve each tool and develop new insights

Their differences don’t fragment the platform. Same learning engine. Shared advantage.

 

MetriDx™

The First Non-Surgical Diagnostic That Confirms and Stages Endometriosis—From a Simple Office Visit

 

HeraFem®

A Real-Time Cervical Cancer Diagnostic That Detects CIN2+ Lesions—No Biopsy, No Lab, No Delay

Sensitivity / Specificity

80% / 95%

 

91% / 65%*

Diagnostic Target

Detects & molecularly stages endometriosis

 

Detects cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions before they become invasive cancer

Data Type

mRNA expression profiling via RT-qPCR

 

Optical & electrical spectroscopy

AI Role

ML model trained on 14B+ datapoints from gene expression

 

On-device AI enables non-invasive classification

Result Timing

3-to-5 days via lab processing

 

Same-visit, point-of care diagnosis

Sample Collection

Pipelle sampling—routine, non-surgical, no anesthesia

 

Cervical scan - no biopsy, no cramping, no lab needed

Care Setting

OB-GYN, fertility clinics, primary care, reference labs

 

OB-GYN, primary care, rural & underserved care environments

Intellectual Property

6 patents

 

2 patents

Regulatory Pathway

LDT, FDA Approval

 

COFEPRIS, FDA Approval

Launch Timeline

U.S. in 2026
Revenue streams turn on pre-FDA approval

 

Latin America in 2025
Revenue streams turned on pre-COFEPRIS clearance

 

 

 

 

*Ongoing study to improve overall accuracy

Clinical Advantages—Built for Frontline Care—Not the OR

Hera doesn’t just accelerate diagnosis. It gives clinicians the power to act with molecular precision and diagnostic control. It’s not an upgrade. It’s what diagnostics should’ve been all along.

The More Diagnoses, The Smarter It Becomes

Every sample sharpens scoring, elevates accuracy, and improves next-patient precision.

Every diagnostic confirmation processed by Hera feeds back into the system—sharpening molecular scoring, elevating diagnostic accuracy, and improving staging rigor for the next patient. This is live, patient-derived data powering machine learning—not theoretical AI.

We don’t train on hope. We train on outcomes. 

Each result trains a faster, more precise path to care.

HeraBiotech Platform Cycle

Intelligence That Compounds

Each result enters the system. New insights generated. Algorithms refine. 

Diagnostic improves—for every patient, every condition, every scan. Biology in. Data out. Action, accelerated.

MetriDx™

MetriDx™

The first accurate alternative to diagnostic laparoscopy—without a scalpel, sedation, or surgery.

For the first time, clinicians have a definitive, low-friction diagnostic tool to confirm and stage endometriosis using sample-level intelligence, right at the point of suspicion.

Tissue-based diagnostic

No sedation, no surgery; sample collection is common practice

First staging tool option

According to rASRM guidelines (I-IV)

Old hardware, new software

RT-qPCR of mRNA biomarkers enhanced by AI-powered algorithms

Accurate results

95% Specificity / 80% Sensitivity

Sign-Up For Launch News

Designed for the Realities of Practice

Hera eliminates abstract pipelines, seamlessly integrating into existing clinical workflows, moving diagnostics downstream.

Clinic & Lab-ready

End-to-end solution from sample collection to diagnostic report

Integrated Workflow

With clinics and diagnostic labs. No extra equipment needed

Fast Turnaround

Diagnostic Report in days

Billable

Proprietary components and workflow enable unique billing opportunity

Meet the experts building it
Test Tubes in a laboratory

HERAfem™

Replaces the outdated, multi-step model with point-of-care detection—no lab, no biopsy, no bottlenecks.

HERAfem™ lets healthcare professionals screen, diagnose, and monitor CIN2+ lesions directly at the cervix, bypassing the step-wise systems that slow diagnosis, introduce variability, and increase dropout.

Direct on tissue, results on display

Powered by AI-platform. No cold chain, No pathology backlog

Optical and electrical spectrometry analysis

Painless and accurate (91% Sensitivity / 65% Specificity*)

Two minutes to diagnosis

Treatment is the next step. No waiting-time anxiety, No followup roulette

Ergonomic and inclusive design

Works on all BMI ranges. No cramping, No spotting

HeraFem
Soon to be available in Latin America, Asia and Africa.
Pre-order HERAfem now

Designed for the Realities of Practice

Hera eliminates abstract pipelines, seamlessly integrating into existing clinical workflows, moving diagnostics downstream.

Clinic & Lab-ready

End-to-end solution from sample collection to diagnostic report

Integrated Workflow

With clinics and diagnostic labs. No extra equipment needed

Fast Turnaround

Diagnostic Report in days

Billable

Proprietary components and workflow enable unique billing opportunity

Meet the experts building it

Turning Diagnostic Losses Into Economic Impact

The cost of postponed diagnosis isn’t just clinical—it’s systemic.

In the U.S. alone, surgical diagnosis of endometriosis drives over $33 billion in spending each year, equivalent to $16.5K per patient to confirm disease already in progress.

MetriDx™ changes that. By replacing surgery with a lab-developed test, it cuts diagnostic cost by ~$17K per patient, down to just 16% of the traditional pathway. At scale, it could eliminate up to 90% of this burden.

Image

Zoom closer, and the returns compound.

MetriDx™ has the potential to generate up to $4M in annual revenue per average fertility clinic by accelerating diagnosis, streamlining referrals, and improving treatment conversion.

This is platform-powered efficiency—built for return at every layer of care.

Where legacy diagnostics drain systems, Hera builds value.

Globally HeraFem® transforms access at the system level.

The Mexico Public Health System (MPHS) enables 3x more women to be screended on the budget, and reduces total cervical cancer costs by ~66%, simply by diagnosis earlier, without lab bottleneck.

Learn Now
Image
Image

The Diagnostic Blind Spot That Spans a Lifetime

Across two of the most prevalent and dangerous conditions in women’s health—endometriosis and cervical cancer—the same story repeats:

Chronic biological progression, missed windows for intervention, and diagnostic systems that were built reactively rather than for proactive intervention.

Endometriosis: A Chronic, Invisible Illness

Affects 10–20% of women—over 200 million globally—yet remains one of the most delayed, misdiagnosed conditions in medicine.

It is the leading cause of female infertility, but its impact reaches far beyond reproduction.

Endometriosis is a debilitating, “whole-body,” chronic inflammatory disorder that rewires immune function, alters gene expression, and spreads across pelvic, gastrointestinal, and neurological systems.

Patients wait an average of 8.3 years for a diagnosis—cycling through OB-GYNs, GI specialists, fertility clinics, and pain centers.

All while the disease silently progresses, causing internal scarring, organ damage, and irreversible systemic disruption.

60+ comorbidities—half at 2x prevalence—underscore the systemic damage of untreated endometriosis.

  • 4× increased risk of ovarian cancer
  • 2.4× risk of endometrial cancer
  • 3.8× risk of osteoporosis

Endometriosis affects every life stage and contributes to 32% of U.S. deaths tied to comorbidity progression later in life.

Until now, diagnosis still relied on invasive laparoscopy, with a 36% miss rate.

This is avoidable harm. And catching it early? Saves lives

Learn Now

Cervical Cancer: Treatable—Yet Still Tragically Undetected

Cervical cancer is a malignant disease triggered by persistent infection with high-risk HPV strains. It progresses silently—through CIN2+ lesions—until cells breach the basement membrane and become invasive.

Caught early, survival exceeds 90%. But detection is often too late.

Diagnosis still relies on a multi-step cascade—Pap, HPV, colposcopy, biopsy—each adding postponement, attrition, and risk. Pap test sensitivity ranges from 55–80%, and the average confirmation lag from an abnormal Pap to diagnosis spans 3 to 11 months.

Meanwhile:

  • VIA (Visual inspection) is highly variable across operators
  • The traditional focus on the transformation zone (TZ) often misses broader pathology
  • Stigma, legal, and cultural barriers with checkups
  • Infrastructure gaps limit access for millions—especially in rural and underserved regions

These aren’t just roadblocks. They’re vectors of harm. 

Each step increases risk. Each dropout costs lives. And once CIN2+ progresses, treatment gets harder, diagnostics become more invasive, cost increases, and less effective.

The window for cure exists—but it’s closing with time. Hera keeps it open.

Image
Image

One Platform. Built for the >100 Million Still Waiting.

Hera's platform isn’t just advanced—it’s deployable.

The same engine that works in U.S. clinics now powers rural diagnostics across Latin America.

Diagnostic innovation means nothing if it can’t reach the women who need it most. Hera is built for both ends of the spectrum—from first-world fertility clinics to underserved health systems—without compromise.

 

  • A platform finally designed for the 100M+ women living in healthcare deserts
  • Cloud-based engine improves and generates insights at every diagnosis
  • MetriDx: Deployable to any RT-qPCR lab
  • HERAfem: No biopsy, pathology, cold chain, BMI limitations

What’s Ahead—From Two Conditions to Dozens of Possibilities

Hera’s diagnostic engine wasn’t built for a single use case. It was built for complexity and is already being adapted to target:

Gynecologic Conditions

Gynecologic Conditions

Driven by tissue disruption, inflammation, & hormonal shifts

Epithelial & Cervical-Adjacent Cancers

Epithelial & Cervical-Adjacent Cancers

Where early detection defines survival

Dermatologic Assessments

Dermatologic Assessments

When biopsies aren’t viable or necessary

As our tools learns from each scan and sample, the next frontier becomes not just possible, but inevitable. This isn’t roadmap speculation—it’s a biologically intelligent diagnostic engine in motion.

Earlier detection reduces escalation, accelerates intervention, and strengthens clinical decision-making, ultimately improving outcomes across every setting.

This isn’t feature creep. Its infrastructure catching up to biology.